Bring groundbreaking
therapeutics to the world.
The newly established Low Institute for Therapeutics (LIFT) is blazing a trail for early-stage therapeutic discovery, bridging the gap between cutting-edge research and real-world impact — all supported by Purdue Research Foundation’s (PRF) proven research-to-commercialization expertise.
LIFT is looking for partners to bring these groundbreaking therapeutics to the world.
By partnering with LIFT, startups, investors, and collaborators will have the unique opportunity to:
- Develop promising therapeutic innovations at a rapid pace.
- Access Purdue’s world-class research ecosystem and PRF’s robust entrepreneurial and commercialization know-how.
- Engage with top-tier subject matter experts.
About the Low Institute for Therapeutics
In 2025, Purdue launched the Low Institute for Foundational Therapeutics , which accelerates Purdue drug innovations by licensing promising technologies from the Purdue Innovates Office of Technology Commercialization and advancing them toward clinical development.
Dr. Philip Low, Purdue’s Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry, is a faculty member in the Purdue Institutes for Drug Discovery and Cancer Research. He holds more than 100 U.S. patents and has founded seven companies.
With the institute, he seeks to replicate the success he’s had moving from research to commercialization in multiple startups — Endocyte, but also On Target Laboratories, Eradivir, Umoja and others. The institute, in partnership with PRF and the university, will share Low’s research-to-commercialization expertise with the broader Purdue ecosystem.
Low and his wife, Joan Low, will donate $20 million over the next five years to support the institute’s mission.
I believe that I have an obligation to develop lifesaving innovations that improve quality of life. My career has always been in pursuit of that goal, and now I’d like to ensure others can do the same. LIFT is a chance to ‘fill the gap,’ getting over the hurdle of funding necessary trials that can often stymie progress for early-stage therapeutics.”
Dr. Philip Low
Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry
Interested in partnering with LIFT?
Start the conversation
"*" indicates required fields